By Annalee Armstrong
It’s all about the proteins for Takeda’s latest pact with molecular engineering company Evozyne. Under a deal worth up to $400 million down the line, they'll work together to develop new proteins that can be incorporated into the next generation of gene therapy for rare diseases.
read more
By Kevin Dunleavy
With Merck taking the reins from retiring CEO Ken Frazier and handing them to Robert Davis at the exact midway point of 2021, how would the New Jersey-based drugmaker divvy up their pay for the year? In an unusual bit of symmetry, while Davis saw his pay package increase by $6.9 million last year, Frazier saw his decline by the same amount.
read more
By Dave Muoio
While the average prices hospitals charged to commercial payers from 2012-2019 were "relatively stable" compared to Medicare on the national level, a new study also found substantial upward and downward movement within individual hospital referral regions.
read more
By Andrea Park
After making its first foray into nonalcoholic steatohepatitis (NASH) drug development with a $1 billion RNAi therapy partnership last fall, GlaxoSmithKline is continuing to carve its own path in the race to develop the first FDA-approved NASH treatment.
read more
By Angus Liu
The multiple R&D, regulatory and commercialization setbacks have hit home for bluebird bio. Hoping to keep the business afloat, the gene therapy specialist has brought out the cost-cutting ax.
read more
By Annalee Armstrong
Anytime an Alzheimer’s disease treatment generates data suggesting it can improve cognitive function, a murmur goes through the patient and caregiver communities. Could this be the one? Sage Therapeutics is presenting a study just like that this week at the American Academy of Neurology’s annual meeting, but the company’s chief development officer Jim Doherty, Ph.D., admits there’s still a lot to learn.
read more
By Paige Minemyer
Walmart Health will start to open its next slate of clinics beginning today, with five locations planned for Florida.
read more
By Angus Liu
BioNTech CEO Ugur Sahin is taking a big pay cut in 2021, but his large stake in the German company he co-founded still qualifies him for billionaire status.
read more
By Max Bayer
Ned Sharpless, head of the National Cancer Institute, is stepping down at the end of the month. His decision to leave is the latest in a string of departures of top leadership at the National Institutes of Health.
read more
By Conor Hale
After eating up about one billion base pairs to fuel its synthetic biology and cell programming efforts, Ginkgo Bioworks is going back for seconds, with another large order from the DNA weaver Twist Bioscience.
read more
By Robert King
More and more lawmakers are putting pressure on CMS to overturn its proposal to have Medicare only cover the Alzheimer's disease drug Aduhelm for beneficiaries in qualifying clinical trials.
read more
By Nick Paul Taylor
Theravance Biopharma’s losing streak is going on and on and on. After going 0 for 3 last year, the biotech added another failure to its portfolio late on Monday when it disclosed a phase 3 flop in a blood pressure disorder and pointed to a subgroup analysis as a potential path forward.
read more
By Andrea Park
In a deal nearly two years in the making, Bioventus has opted to acquire fellow orthopedic devicemaker CartiHeal—less than a week after CartiHeal announced its flagship cartilage repair implant Agili-C had been approved by the FDA.
read more
By Rebecca Torrence
FDA Commissioner Robert Califf, M.D., and others urged healthcare to prioritize rural residents and non-White patients in health data reform efforts at the 2022 Health Datapalooza and National Health Policy Conference in Arlington, VA.
read more
